Attached files
| file | filename |
|---|---|
| EX-99 - EXHIBIT 99.1 - UNIGENE LABORATORIES INC | ugne20130517_8kaex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 14, 2013
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
0-16005 |
22-2328609 | ||
|
(State or other jurisdiction of |
(Commission |
(I.R.S. Employer | ||
|
|
|
|
|
|
|
81 Fulton Street, Boonton, New Jersey |
07005 | |||
|
(Address of principal executive offices) |
(Zip Code) | |||
(973) 265-1100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
☐ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
This Form 8-K/A amends the Form 8-K that was filed by Unigene Laboratories Inc. on May 14, 2013 solely to move the disclosure to Item 2.02 - Results of Operations and Financial Condition.
Section 2 – Financial Information
Item 2.02 Results of Operations and Financial Condition.
On May 14, 2013, Unigene Laboratories, Inc. issued a press release announcing the financial results for the quarter ended March 31, 2013 and provided a corporate update on the Company’s financial condition and strategic initiatives. A copy of the press release is furnished as Exhibit 99.1 to this report.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Document Description | |
|
99.1 |
Press Release dated May 14, 2013 | |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
UNIGENE LABORATORIES, INC. | |||
|
By: |
/s/ Ashleigh Palmer | ||
|
Ashleigh Palmer, Chief Executive Officer | |||
|
Date:May 17, 2013 | |||
Exhibit Index
|
Exhibit No. |
Document Description | |
|
99.1 |
Press Release dated May 14, 2013 |